Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]T. Plazek: Risk from exposure to arylamines from consumer products and hair dyes. Front. Biosci., Elite, 2:1169-1183 (2010)

  • [2]N. Puvaneswari, J. Muthukrishnan and P. Gunasekaran: Toxicity assessment and microbial degradation of azo dyes. Indian J. Exp. Biol., 44:618-626 (2006)

  • [3]K.-T. Chung, G. E. Fulk, and M. Egan: Reduction of azo dyes by intestinal anaerobes. Appl. Environ. Microbiol., 35:558-562 (1978)

  • [4]K.-T.Chung, G.E. Fulk and A. W. Andrews: Mutagenicity testing of some commonly used dyes. Appl. Environ. Microbiol., 42:641-648 1981)

  • [5]K.-T. Chung, S. E. Stevens, Jr. and C. E. Cerniglia: The reduction of azo dyes by the intestinal microflora. Crit. Rev. Microbiol., 18:175-190; 18:175-190 (1992a)

  • [6]K. T. Chung and C. E. Cerniglia: Mutagenicity of azo dyes: structure-activity relationships. Mutat. Res., 277:201-220 (1992b)

  • [7]K.-T.Chung, and S. E. Stevenson, Jr.: Degradation of azo dyes by environmental microorganisms and helminths. Environ. Toxicol. Chem., 12:2121-2132 (1993)

  • [8]T. Plazek, C. Lang, G. Grohmann, U. S. Gi, and W. Bates: Formation of a carcinogenic aromatic amine from an azo dye by human skin bacteria in vitro. Human Exp. Toxicol., 18:552-559 (1999)

  • [9]American Cancer Society: Cancer Facts & Figures 2013. Atlanta, Ga. (2013)

  • [10]T. A. Chiang, Pei-Fen W., L. S.Ying, L. F. and Y. C. Ko: Mutagenicity and aromatic amine content of fumes from heated cooking oil produced in Taiwan. Food Chem. Toxicol., 37 (2-3):125-134 (1999)

  • [11]K. E. Richardson, P. P. Fu and C. E. Cerniglia: Metabolism of 1-, 3-and 6-nitrobenzo(a)pyrene by intestinal microflora. J. Toxicol. Environ. Health, 23:527-537(1988)

  • [12]P. P. Fu: Metabolism of nitro-polycyclic aromatic hydrocarbon. Drug Metab. Rev., 22:209-268 (1990)

  • [13]F. Rafii, W. Franklin, R. Heflich and C. E. Cerniglia: Reduction of nitrated compounds by anaerobic bacteria isolated from the human gastroinestinal tract. Appl. Environ. Microbiol., 57:962-968 (1991)

  • [14]L. Stayner, A. Dannenberg, T. Bloom and M. Thun: Excess hepatobiliary cancer mortality among munition workers exposed to dinitrotoluene. J. Occup. Med., 35 (3):291-296 (1993)

  • [15]H. S. Rosenkranz and D. R. Sanders: Nitropyrenes: isolation, identification, and reduction of mutagenic impurities in carbon black toners. Science, 209:1039-1043 (1980)

  • [16]H. S. Rosenkranz, H. S. and R. Mermelstein: Mutagenicity and genotoxicity of nitropyrenes. All nitro-containing chemicals were not created equal. Mut. Res., 114:217-267 (1983)

  • [17]Y. Ohnishi, H. Kinouchi, H. Tsutsu and M. Uejim: Mutagenic nitropyrenes in foods. pp.107-118. In: Y, Hayashi, et al. (ed.), Diet, Nutrition and Cancer. Japan Science Society Press, Tokyo (1986)

  • [18]H. Tokiwa, T. Otofji, R. Nakagawa, K. Horikawa, T. Maeda, S. Sano, K. Izumi and H. Otsuka: Dinitro derivatives of pyrene and fluoranthrene in diesel emission particulates and their tumorigenicity in mice and rats. Dev. Toxicol. Environ. Sci., 13:253-270 (1986)

  • [19]D. D’Cruz: Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol. Lett., 113:421-432 (2000)

  • [20]A. Martelli and G. Brambilla: Arylamines drugs: genotoxic carcinogenic activity of NO-derivatives. Front. Biosci., E4:2071-2084 (2012)

  • [21]S. Fujita and J. Peisach: The stimulation of microsomal azoreduction by flavins. Biochem. Biophys. Acta., 719:179-189 (1982)

  • [22]A. Riefe: Dyes:environmental chemistry. In Howe-Grant, M., (Ed.) Kirk-Othmer Encyclopedia of Chemical Technology, Fourth ed., vol.8. Wiley. New York. pp. 753-783 (1992)

  • [23]E. J. Weber and R. L. Adams: Chemical-and sediment-mediated reduction of the azo dye Disperse Blue 79. Environ. Sci. Technol., 29:1163-1170 (1995)

  • [24]E. J. Weber: Iron-mediated reductive transformation: investigation of reaction mechanism. Environ. Sci. Technol., 30:716-719 (1996)

  • [25]E. K. Keck, J. Klein, M. Kudlich, A. Stolz, H. J. Knackmuss and R. Mattes: Reduction of azo dyes by redox mediators originating in the naphthalene sulfonic acid degradation pathway of Sphingomonas sp. strain BN6. Appl. Environ Microbiol., 63(9):3684–3690 (1997)

  • [26]S. Nam and V. Renganatham: Non-enzymatic reduction azo-dyes by NADH. Chemophere, 40:351-357 (2000)

  • [27]K.-T.Chung and G. S. Gadupudi: Possible Roles of excess tryptophan metabolites in cancer. Environ. Mol. Mutagen., 52:81-169 (2011)

  • [28]D. P. Rose: Aspects of tryptophan metabolism in health and disease: a review. J. clinical pathol., 25:17-25 (1972)

  • [29]D. F. Birt, A. D. Julius, R. Hasegawa, M. St. John and S. Cohen: Effect of L-tryptophan excess and vitamin B6 deficiency on rat urinary bladder cancer promotion. Cancer Res., 47:1244-1250 (1986)

  • [30]H. Sidransky: Tryptophan and carcinogenesis: review and update on how tryptophan may act. Nutrit. Canc., 29:181-194 (1997)

  • [31]A. Bertazzo, E. Ragazzi, M. Biasiolo, C. V. L. Costa and A. Allegri: Enzymes activities involved in tryptophan metabolism along kynurenine pathway in rabbit. Bioch. et Biophys 1527:167-175 (2001)

  • [32]L. Rehn: Bladder tumour in fuchsin workers (Ger) Arch. Klin. Chir., 50:588-600 (1895)

  • [33]W. C. Hueper: Occupational tumors and allied diseases (1942)

  • [34]C. A. Veys: Bladder tumours and occupation: a coroner’s notification scheme. Brit. J. Ind. Med., 31:65-71 (1974)

  • [35]C. A. Veys: Bladder tumors in rubber workers: a factory study 1946-1995. Occup. Med., (Oxford, England), 54, 322-329 (2004)

  • [36]N. D. Freedman, D. T. Silverman, A. R. Hollenbeck, A. Schatzkin and C. C. Abnet: Association between smoking and risk of bladder cancer among men and women. J. Amer. Med. Assoc., 306:737-745 (2011)

  • [37]M. Ploeg, K. K. H. Aben and L. A. Kienaney: The present and further burden of urinary bladder cancer in the world. World J. Urol., 27:289-293 (2009)

  • [38]J. Jemal, J., F. Bray, M. M. Center, F Ferlay, E. Ward, and D. Forman: CA Cancer J. Clin., 61:69-90 (2011)

  • [39]A. Jemal, R. Siegel, E. Ward, Y. Hao and J. Xu: Cancer statistics. CA Cancer J. Clin., 58:71-96 (2008)

  • [40]K.-T. Chung: Occurrence, uses, and carcinogenicity of arylamines. Front. Issue: Front. Biosc., Elite, 7:367-393 (2015)

  • [41]O. G. Prokofeva: Liver tumor induction by benzidine in mice. Vopr. Onkol., 17:61-64 (1971)

  • [42]IARC: Some aromatic amines, organic dyes, and related exposures. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France.Vol.99:1-692 (2010)

  • [43]IARC: Some industrial chemicals and dyestuffs. IARC Monographs on the Evaluation Carcinogenic Risks to Humans, Lyon, France. Vol.29:1-398 (1982)

  • [44]ATSDR: Toxicological profile for benzidine: Atlanta, GA: U. S. Department of Health and Human Services, Agency to Toxic Substances and Diseases Registry (2001)

  • [45]A. Püntener and C. Pages: European on certain azo dyes (2013) www.tfl.com.

  • [46]N. Mathur, P. Bhatgagar and P. Sharma: Review of the mutagenicity of textile dye products. Universal Environ. Res. Technol., 2:1-18 (2012)

  • [47]M. Sitta: Handbook of Toxic and Hazardous Chemicals and Carcinogens. 2nd ed. Noyes Publications, Park Ridge, New Jersey (1985)

  • [48]M. J. Stasik:Urinary bladder cancer after 4-chloro-o-toluidine. Dtsch. med. Wschr, 116:1444-1447 (1991) (in German) (1991)

  • [49]M. M. Reidenberg: Aromatic amines and the pathogenesis of lupus erythematosus. Amer. J. Med., 75:1037-1042 (1983)

  • [50]S. W. Finks, A. L. Finks and T. H. Self: Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med. J., 99:18-22 (2006)

  • [51]J. D. Carter, J. Valeriano-Marcet, K. S. Kanik, and F. B. Vasey: Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South. Med. J., 94:1122-1123 (2001)

  • [52]R. L. Rubin and A. Kretz-Rommel: Initiation of autoimmunity by reactive metabolites of a drug in the thymus. Environ. Health Persp., 107 (suppl. 5): 803-807 (1999)

  • [53]A. T. Borchers, C. L. Keen and M. E. Gershwin: Drug-induced lupus. Ann. N.Y. Acad, Sci., 1108:166-188 (2007) New York Academy of Sciences.

  • [54]A. Mak and S. H. Tay: Environmental factors: toxicants, and systemic lupus erythematosus. Int. J. Mol. Sci., 15:16043-16056 (2014)

  • [55]M. Murata and S. Kawanish: Mechanisms of oxidative DNA damage induced by carcinogenic arylamines, Front. Biosci., 16:1132-1143 (2011)

  • [56]F. F. Kadlubar, J. A. Miller and E. C. Miller: Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxyarylamine in relation to urinary bladder carcinogenesis. Canc. Res., 37:805-814 (1977)

  • [57]S. Ning, and X. Xiaobai: Reductive mechanism of 4-aminobiphenyl by rat liver fraction. Carcinogen., 18:1233-1240 (1997)

  • [58]F. F. Kadlubar, P. P. Fu, H. Jung, A. U. Shaikh and F. A. Beland: The metabolic N-oxidation of carcinogen arylamines in relatiomn to nitrogen charge density and oxidation potential. Environ. Health Perspect., 87:233-236 (1990)

  • [59]P. L. Skipper and S. R. Tannenbaum: Molecular dosimetry of aromatic amines in humanpopulations. Environ. Health Perspect.,(102) (supplement) 6:17-21 (1994)

  • [60]G. Talaska, M. Schamer, P. Schamer, P. Skippert, S. Tannenbaum, N. Caporaso, F. Kadlubar, H. Bartsch and P. Vineis: Carcinogen-DNA adducts in exfoliated urothelial cells techniques for non-invasive human monitoring. Environ. Health Perspect., 99:289-291 (1993)

  • [61]F. Saletta, G. Matullo, M. Manuguerra, S. A. Bardelli and P. Vineis: Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. Cancer Res., 67:7088-7094 (2007)

  • [62]P. D. Josephy and M. Novak: Reactive electrophilic metabolites of aromatic amine and amide carcinogens. Front. Biosc., S5,:341-359 (2013)

  • [63]S. Ohnishi, M. Murata, M., Degawa, M. and S. Kawanishi: Oxidative DNA damage induced by an N-hydroxy metabolite of carcinogenic 4-aminoaminoazobenzene. Jpn. J. Cancer Res., 92:23-29 (2001)

  • [64]P. S. Makena and K. T. Chung: Evidence of oxidative genotoxicity induced by 4-aminobiphenyl, benzidine, and benzidine congeners. Environ. Mol. Mutagen., 48:404-413 (2007a)

  • [65]M. W. Anderson, S. H. Reynolds, M. You and R Maronpot: Role of protoncogene activation in carcinogenesis. Environ. Health Perspect., 98:13-24 (1992)

  • [66]I. Menashe, J. D. Figueroa, M. Garcia-Closas, N. Chatterjee, N. Malats, A. Picornell, D. Maeder, Q. Yang, L. Prokunina-Olsson, Z. Wang, F. X. Real, K. B. Jacobs, D. Baris, M. Thun, D. Albanes, M. P. Purdue, M. Kogevinas, A. Hutchinson, Y.-P. Fu, W. Tang, Affiliations: Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Municipal Institute of Medical Research, Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, National School of Public Health, Athens, Greece L.urdette, A. Tardón, C. Serra, A. Carrato, R. García-Closas, J. Lloreta, A. Johnson, A. Schned, G. Andriole Jr., A. Black, E. J. Jacobs, R. W. Diver, S. M. Gapstur, S. J. Weinstein, S. N. E. Caporaso, M. T. Landi, J. F. Fraumeni Jr., S. J. Chanock, D. T. Silverman, and T. Rothman: Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. Plos One, 7:e29396 (2012)

  • [67]A. P. Feinberg:The epigenetics of cancer etiology. Seminars in Cancer Biol., 14:6427–432 (2004)

  • [68]K.-T.Chung: Major hypotheses of carcinogenesis revisited. In: Handbook of Cancer Models with Applications. In Series in Mathematical Biology and Medicine. Vol.9. Chapter 8, Page 225-289, Tan, W. Y. and Hanin, L. (ed.), World Scientific, New Jersey (2008)

  • [69]A. H. Hofstra, S. M Li-Muller and J. P. Uetrecht: Metabolism of isoniazid by activated leukocytes. possible role in drug-induced lupus. Drug Metab. Dispos., 20:205-210 (1992)

  • [70]R. L. Rubin and J. T. Cumutte: Metabolism of procainamide to cytotoxic hydroxylamine by neutrophils activated in vitro. J. Clin. Invest., 83:1336-1343 (1989)

  • [71]X. Jiang, G. Khursigara and R. L. Rubin: Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science, 266 (5186): 810-813 (1994)

  • [72]D. P. Suites, A. Terr 1, Parslow and G. Tristram: Basic Clinical Immunology. Norwalk, CT, Appleton & Lange. p.373 (1994) ISBN 0-8385-0561-9.

  • [73]A. Hofstra, I. Matassa and J. Uetrwcht: Metabiolism of hydralazine by activated leukocytes: implications for hydralazine induced lupus. J. Rheumatol., 18(11): 1673-1680 (1991).

  • [74]A. Hofstra: Metabolism of hydralazine: relevance to drug-induced lupus. Drug Metab. Rev., 26(3):485-505 (1994).

  • [75]T. J. Thomas and R. P. Messner: Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthri. Rheum., 29:638-645 1986)

  • [76]W. Zacharias and W. J. Koopman: Lupus-inducing drugs alter the structure of supercoiled circular domains. Arthri. Rheum., 33(3):366-374 (1990)

  • [77]Q.-W. Ma, G.-f. Lin, J.-F. Chen, W.-C. Guo, Y-Q. Qin, K. Golka and J.-H Shen: N-Acetyltransferase 2 genotype, exfoliated urothelial cells and benzidine exposure. Front. Bios., Elite 4:1966-1974 (2012)

  • [78]R. G. Lahita: Systemic Lupus Erythematosus. New York: John Wiley & Sons.859. ISBN 0-471-87388-8 (1987)

  • [79]S. W. Finks, A. L. Finks and T. H. Self: hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med. J., 99:18-22 (2006)

  • [80]M. Usha: Impact analysis of industries in Sanganer. P. G. Diploma Field Study Report Submitted to Indira Gandhi Center for HEEPS, University of Rajasthan, Jaipur (India) (1989)

  • [81]R. Benigni and L. Passerini: Carcinogenicity of the aromatic amines: from structure activity relationships to mechanisms of action and risk assessment. Mutat. Res., 511:191-206 (2002)

  • [82]P. S. Makena and K. –T. Chung: Effects of various polyphenols on bladder carcinogens benzidine-induced genotoxicity. Food Chem. Toxicol., 45:1899-1909 (2007b)

  • [83]J. D. Carter. J. Valeriano-Marcet, K. S. Kanik and F. B.Vasey:Antinuclear antibody negative drug-induced lupus caused by lisinopril. South Med. J., 112-1123 (2001)

  • [84]R. L. Yung, J. Quddus, C. E. Chrisp, K. J. Johnson, B. C. Richardson: Mechanisms of drug-induced lupus.1. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause atoimmunity in vitro. J. Immunol., 154:3025-3035-(1995)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Carcinogenicity, allergenicity, and lupus-inducibility of arylamines

King-Thom Chung 1,*
Affiliation
Article Info

1 Department of Biological Sciences, University of Memphis, Memphis, Tennessee 38152

*Author to whom correspondence should be addressed.

 

Abstract

Arylamines are widely used in food, drugs, and cosmetics as well as other industries. These chemicals are present ubiquitously in cigarette smoke, smoke emitted from cooking fume hoods as well as are generated by diverse industries. Arylamines can be generated by cleavage of azo dyes by intestinal and skin microbiota. Some arylamines are used as drugs while others are constituents of human metabolism. Many of the arylamines are mutagenic and carcinogenic. They are generally recognized as the major cause of human bladder cancer, but arylamines can induce cancers of other organs in humans and animals. Some arylamines are allergenic, causing lupus like syndrome, or other maladies. In view of their unbiquitious nature and the diseases they cause, arylamines are probably the most important chemicals causing health problems.

Keywords

  • Arylamine
  • Carcinogen
  • allergen
  • Aromatic amines Lupus Erthytomatosus
  • Review

References